<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>OASIS-5</h3></div><p><span class="main">"Fondaparinux versus Enoxaparin in Acute Coronary Syndromes (OASIS-5 Trial)" The New England Journal of Medicine. 2006. 354(14):1464-1476.  </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/OASIS-5>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa055443>Full Journal Article</a>
                                        </span></p><p><span class="main">Contents
 </span></p><p><span class="main">1. Clinical Question
2. Bottom Line
3. Major Points
4. Guidelines
5. Design
6. Population
    6.1 Inclusion Criteria
    6.2 Exclusion Criteria
    6.3 Baseline Characteristics
7. Interventions
8. Outcomes
    8.1 Primary Outcome
    8.2 Secondary Outcomes
9. Criticisms
10. Funding
11. Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">In patients with acute coronary syndromes, does fondaparinux, compared to enoxaparin, reduce ischemic events without increasing bleeding?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Fondaparinux was noninferior to enoxaparin in preventing ischemic events in acute coronary syndromes, significantly reduced major bleeding, and improved long-term mortality and morbidity.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Fondaparinux, a synthetic pentasaccharide, potentially offers a better bleeding profile than enoxaparin while providing comparable anticoagulant effects for ischemic event reduction in acute coronary syndromes.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Recommendations for the use of fondaparinux may be influenced by these findings; however, specific guidelines resulting from this trial could vary by organization.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Multicenter, double-blind, randomized controlled trial
- N=20,078 patients with acute coronary syndromes
- Fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kg twice daily)
- Mean follow-up: 6 months
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Inclusion Criteria: Patients with acute coronary syndromes, specifically unstable angina or myocardial infarction without ST-segment elevation, within 24 hours of symptom onset
- Exclusion Criteria: Contraindications to low-molecular-weight heparin, recent hemorrhagic stroke, other indications for anticoagulation, serum creatinine â‰¥3 mg/dL
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Fondaparinux 2.5 mg subcutaneously once daily plus placebo enoxaparin
- Enoxaparin 1 mg per kg subcutaneously twice daily plus placebo fondaparinux
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- Primary Outcome: Death, myocardial infarction, or refractory ischemia at nine days; major bleeding events
- Secondary Outcomes: Death, myocardial infarction, refractory ischemia, strokes at 30 days and at 180 days, major bleeding events throughout the study
 </span></p><h2><span class="labels">Criticisms</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">- The study design and patient selection could potentially impact the generalizability of the trial results to broader acute coronary syndrome populations.
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">The trial was supported by Sanofi-Aventis, Organon, and GlaxoSmithKline. Disclosure of potential conflicts of interest by the trial's authors included receipt of consulting fees, lecture fees, and research grants from the pharmaceutical companies supporting the trial.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Additional readings include publications in cardiovascular medical journals discussing the impact of bleeding on acute coronary syndrome outcomes and the usage of fondaparinux in clinical practice. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>